share_log

B of A Securities Initiates Coverage On Sutro Biopharma With Buy Rating, Announces Price Target of $12

Benzinga ·  May 8 06:16

B of A Securities analyst Tazeen Ahmad initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment